Cellectar Biosciences, Inc. CLRB
1.30 USD +0.08 (+6.56%)
Nov 3, 2026, 3:22 PM EST
1.23 Day range 1.31
1.12 52-week range 4.70
- YTD
- -55.93%
- 1 year
- -60.61%
Analyst view
Consensus: buy
Buy
Price target (mean) 5.67 +335.9% upside
Now 1.30
- Target (low)
- 1.00
- Target (mean)
- 5.67
- Target (high)
- 13.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 3
- 2 months ago 3
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.3525 | -0.43 – -0.32 | -0.40 | +11.9% | 0 | 0.0% | 4 |
| Next quarter | -0.195 | -0.26 – -0.16 | -0.74 | +73.7% | 0 | 0.0% | 4 |
| Current year | -1.57 | -1.73 – -1.39 | -3.11 | +49.6% | 0 | 0.0% | 4 |
| Next year | -0.6825 | -0.77 – -0.63 | -1.57 | +56.5% | 10.09M | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Oppenheimer | Downgrade | Outperform | Perform |
| Nov 19, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 28, 2024 | Roth MKM | Maintained | Buy | Buy |
| Mar 28, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 4, 2024 | Roth MKM | Reiterated | Buy | Buy |
| Nov 4, 2022 | HC Wainwright & Co. | Maintained | — | Buy |